{'52WeekChange': 0.7488445,
 'SandP52WeekChange': None,
 'address1': 'Baarerstrasse 14',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 90.44,
 'askSize': 1100,
 'averageDailyVolume10Day': 810762,
 'averageVolume': 1101358,
 'averageVolume10days': 810762,
 'beta': 2.33419,
 'beta3Year': None,
 'bid': 90.35,
 'bidSize': 1100,
 'bookValue': 14.552,
 'category': None,
 'circulatingSupply': None,
 'city': 'Zug',
 'companyOfficers': [],
 'country': 'Switzerland',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 90.83,
 'dayLow': 87.22,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': 169.487,
 'enterpriseToRevenue': 16.152,
 'enterpriseValue': 4674632704,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 78.50657,
 'fiftyTwoWeekHigh': 97.824,
 'fiftyTwoWeekLow': 32.3,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 50681918,
 'forwardEps': -5.21,
 'forwardPE': -17.34165,
 'fromCurrency': None,
 'fullTimeEmployees': 304,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.20944999,
 'heldPercentInstitutions': 0.55734,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/crisprtx.com',
 'longBusinessSummary': 'CRISPR Therapeutics AG, a gene editing company, '
                        'focuses on developing transformative gene-based '
                        'medicines for serious human diseases. It develops its '
                        'products using Clustered Regularly Interspaced Short '
                        'Palindromic Repeats (CRISPR)/CRISPR-associated '
                        'protein 9 (Cas9), a gene editing technology that '
                        'allows for precise directed changes to genomic DNA. '
                        'It has a portfolio of therapeutic programs in a range '
                        'of disease areas, including hemoglobinopathies, '
                        'oncology, regenerative medicine, and rare diseases. '
                        "The company's lead product candidate is CTX001, an ex "
                        'vivo CRISPR gene-edited therapy for treating patients '
                        'suffering from transfusion-dependent beta thalassemia '
                        "or severe sickle cell disease in which a patient's "
                        'hematopoietic stem cells are engineered to produce '
                        'high levels of fetal hemoglobin in red blood cells. '
                        'It is also developing CTX110, a donor-derived '
                        'gene-edited allogeneic CAR-T therapy targeting '
                        'cluster of differentiation 19 positive malignancies. '
                        'In addition, the company is developing allogeneic '
                        'CAR-T programs comprising CTX120 targeting B-cell '
                        'maturation antigen for the treatment of multiple '
                        'myeloma; and CTX130 for the treatment of solid tumors '
                        'and hematologic malignancies. Further, it engages in '
                        'developing regenerative medicine programs in '
                        'diabetes; and in vivo and other genetic disease '
                        'programs to treat glycogen storage disease Ia, '
                        'Duchenne muscular dystrophy, and cystic fibrosis. The '
                        'company has strategic partnerships with Bayer '
                        'Healthcare LLC, Vertex Pharmaceuticals Incorporated, '
                        'and ViaCyte, Inc. CRISPR Therapeutics AG is '
                        'headquartered in Zug, Switzerland.',
 'longName': 'CRISPR Therapeutics AG',
 'market': 'us_market',
 'marketCap': 6204306944,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_262549448',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': 45535000,
 'nextFiscalYearEnd': 1640908800,
 'open': 88.9,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '41 41 561 3277',
 'previousClose': 90.8,
 'priceHint': 2,
 'priceToBook': 6.2087684,
 'priceToSalesTrailing12Months': 21.437109,
 'profitMargins': 0.15732999,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 90.83,
 'regularMarketDayLow': 87.22,
 'regularMarketOpen': 88.9,
 'regularMarketPreviousClose': 90.8,
 'regularMarketPrice': 88.9,
 'regularMarketVolume': 986175,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 68669696,
 'sharesPercentSharesOut': 0.0665,
 'sharesShort': 4137765,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 3886113,
 'shortName': 'CRISPR Therapeutics AG',
 'shortPercentOfFloat': 0.077,
 'shortRatio': 4.12,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'CRSP',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': 0.766,
 'trailingPE': 117.95039,
 'twoHundredDayAverage': 59.24338,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '10230d3e-917c-3849-a2ff-4a032541eb82',
 'volume': 986175,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.crisprtx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '6300'}